In this study, we analyzed the potential of targeting the key regulator of DL/gemcitabine network, the protein c-FLIPL, in pancreatic cancer cells, which has been reported to be a promising target in this type of cancer. This evidence concerns the gene CFLAR and pancreatic neoplasm.